23andMe Reports FY2023 Second Quarter Financial Results
November 07, 2022 16:01 ET
|
23andMe Holding Co.
Second quarter revenue grew 37% to $76 millionConsumer revenue grew 27% year over year due to the addition of telehealth revenueOn track to achieve FY2023 financial guidance SOUTH SAN FRANCISCO,...
23andMe Trials-in-Progress Poster Details Expansion Cohorts for 23ME-00610, an Investigational Antibody Targeting CD200R1, at The Society for Immunotherapy of Cancer’s (SITC) 2022 Annual Meeting
November 07, 2022 08:00 ET
|
23andMe Holding Co.
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading human genetics and biopharmaceutical company with a mission to help people...
23andMe Granted New FDA Clearance to Provide Interpretive Drug Information for a Commonly Prescribed Cholesterol Medication
October 27, 2022 06:45 ET
|
23andMe Holding Co.
SOUTH SAN FRANCISCO, Calif., Oct. 27, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading human genetics and biopharmaceutical company with a mission to help people...
23andMe to Report FY2023 Second Quarter Financial Results
October 24, 2022 16:05 ET
|
23andMe Holding Co.
SOUTH SAN FRANCISCO, Calif., Oct. 24, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading human genetics and biopharmaceutical company with a mission to help people...
23andMe to Present at Upcoming Investor Conferences
October 12, 2022 16:10 ET
|
23andMe Holding Co.
SOUTH SAN FRANCISCO, Calif., Oct. 12, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading human genetics and biopharmaceutical company with a mission to help people...
23andMe Announces Trials-in-Progress Poster Presentation on 23ME-00610, An Investigational Antibody Targeting CD200R1, at The Society for Immunotherapy of Cancer’s (SITC) 2022 Annual Meeting
October 05, 2022 08:21 ET
|
23andMe Holding Co.
SOUTH SAN FRANCISCO, Calif., Oct. 05, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading human genetics and biopharmaceutical company with a mission to help people...
Daniel Chu Joins 23andMe as Chief Product Officer
September 19, 2022 06:45 ET
|
23andMe Holding Co.
SUNNYVALE, Calif., Sept. 19, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, today appointed Daniel Chu as Chief Product...
23andMe Reports FY2023 First Quarter Financial Results
August 08, 2022 16:05 ET
|
23andMe Holding Co.
First quarter revenue grew 9% to $64.5 millionConsumer revenue grew 17% year over year due to the addition of telehealth revenueOn track to achieve FY2023 financial guidance SOUTH SAN FRANCISCO,...
23andMe to Report FY2023 First Quarter Financial Results
July 25, 2022 16:05 ET
|
23andMe Holding Co.
SOUTH SAN FRANCISCO, Calif., July 25, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, announced today that it will report...
23andMe Reports FY2022 Fourth Quarter and Full Year Financial Results
May 26, 2022 16:05 ET
|
23andMe Holding Co.
Achieved FY2022 financial guidanceFourth quarter and full year revenues of $101 million and $272 million representing 14% and 11% increases over prior year, respectivelyNew genomic health services...